JUN

Across TCGA pan-cancer cohorts, JUN mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated JUN data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher JUN mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated JUN expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where JUN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.729	0.911	.010	9	view →
LUAD	OS	Median	All	0.834	0.621	.030	6	view →
CCRCC	DFS	Tertile	All	0.989	0.851	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

JUN–HNSC (DFS)

Open the HNSC breakdown →